Rahil Rafeedheen, MD
Interventional Cardiology · Bowling Green, KYNPI 1649526716
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (28.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 73.7% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $15,919, 2.5 times the $6,258 reported in 2019.
Across 306 payments — averaging $99.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$22K
- Medtronic$2K
- Edwards Lifesciences$2K
- Johnson & Johnson$615
- Boston Scientific$613
- Abiomed$485
- plus $2K from 27 others
What the payments were for
- Consulting fees$7,41824%
- Speaking & faculty fees$6,10020%
- Travel & lodging$8,54728%
- Food & beverage$8,39527%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 64 | $22,491 |
| Medtronic(2 entities) | 37 | $2,313 |
| Edwards Lifesciences | 26 | $1,634 |
| Johnson & Johnson | 42 | $615 |
| Boston Scientific | 17 | $613 |
| Abiomed | 7 | $485 |
| Pfizer | 18 | $292 |
| Novartis | 21 | $290 |
| Inari Medical, Inc. | 3 | $173 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $172 |
| Bard Peripheral Vascular, Inc. | 2 | $168 |
| Shockwave Medical, Inc | 8 | $167 |
| Amgen | 10 | $146 |
| Cardiovascular Systems Inc. | 2 | $130 |
| Stryker | 1 | $122 |
| Sanofi | 1 | $90 |
| Chiesi USA, Inc. | 4 | $84 |
| Actelion Pharmaceuticals US, Inc. | 5 | $67 |
| Novo Nordisk | 3 | $66 |
| Amarin Pharma, Inc. | 4 | $57 |
| Terumo Medical Corporation | 3 | $55 |
| W. L. Gore & Associates, Inc. | 1 | $52 |
| AstraZeneca | 4 | $50 |
| Boehringer Ingelheim | 2 | $42 |
| Merck | 2 | $26 |
| Merge Healthcare Incorporated | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Braemar Manufacturing, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$9,962
- Ultreon$8,066
- Omnilink Elite vascular stent system$1,105
- Mitra Clip system$1,006
- Edwards SAPIEN 3 Transcatheter Heart Valve$706
- COUGAR$683
- COREVALVE EVOLUT R$576
- OPTIS$554
- Xience V coronary stent system$467
- EVOQUE$254
- HI-TORQUE BALANCE$170
- LUTONIX$154
- AVVIGO Guidance System$144
- Optis Coronary Imaging System$135
- FlowTriever$122
- CROSSBOSS$107
- Peripheral Orbital Atherectomy System$100
How this compares
$30,530 in reported general payments places this provider in the 80th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $99,986 |
| XareltoRivaroxaban | 58 | $57,165 |
| EntrestoSacubitril/Valsartan | 61 | $52,446 |
| FarxigaDapagliflozin Propanediol | 40 | $23,556 |
| Repatha SureclickEvolocumab | 24 | $16,021 |
| BrilintaTicagrelor | 13 | $8,360 |
| Diltiazem 12hr ErDiltiazem Hcl | 21 | $8,208 |
| Ranolazine ErRanolazine | 68 | $3,538 |
| Atorvastatin Calcium | 172 | $1,287 |
| Metoprolol Tartrate | 189 | $1,242 |
| Amlodipine Besylate | 276 | $1,038 |
| ClopidogrelClopidogrel Bisulfate | 110 | $1,028 |
| Metoprolol Succinate | 109 | $733 |
| Furosemide | 100 | $542 |
| Losartan Potassium | 75 | $524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $99,986109 claims |
| Johnson & JohnsonXarelto | $615 | $57,16558 claims |
| NovartisEntresto | $290 | $52,44661 claims |
| AstraZenecaFarxiga, Brilinta | $50 | $31,91753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Bowling Green
- Sandeep ChhabraBowling Green$18K
- Mohammed KazimuddinBowling Green$17K
- Mohammad Abdul WaheedBowling Green$10K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.